Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (253)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
CPI-1205 (EZH2 Inhibitor) |
EZH2 Inhibitor | Hematologic | ||
|
Molecule
CPI-1205 (EZH2 Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
||||
Crenolanib |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Crenolanib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Crizotinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Crizotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Dacomitinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Dacomitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Dalpiciclib |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
Dalpiciclib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Defactinib |
Focal Adhesion Kinase (FAK) Inhibitor | Solid Tumour | ||
|
Molecule
Defactinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Focal Adhesion Kinase (FAK) Inhibitor |
||||
Delanzomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Delanzomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
Derazantinib |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Derazantinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Dinaciclib |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
Dinaciclib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Divarasib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Divarasib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Donafenib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Donafenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Dovitinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Dovitinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
CPI-1205 (EZH2 Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 Inhibitor |
|
CrenolanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
CrizotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
DacomitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
DalpiciclibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
DefactinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Focal Adhesion Kinase (FAK) Inhibitor |
|
DelanzomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|
DerazantinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
DinaciclibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
DivarasibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
DonafenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
DovitinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|